News
Here, we share stories about our research, innovations in biotechnology, partnerships, and the people behind our mission to support better health from within. Stay informed, stay inspired, and explore how BLS Pharmaceuticals Ltd continues to advance science for a healthier tomorrow.
Bioxyne partners with Aurora Cannabis
Australian Bioxyne Limited has signed a manufacturing agreement with global medical cannabis company Aurora Cannabis Inc., marking a significant step...
Manufacturing deal signed between Bioxyne and Aurora Cannabis for medicinal products
Bioxyne Limited has announced a new manufacturing agreement with Aurora Cannabis Inc., placing manufacturing at the center of a partnership...
Vantage Point Podcast: Inside Bioxyne: The ASX’s Profitable Play on Medicinal Cannabis, MDMA & Psilocybin
In this episode, we sit down with Sam Watson, managing director of Bioxyne (BXN:ASX), to unpack how the company is...
ASX Briefs: How GMP MDMA and Psilocybin are reshaping access for treatment-resistant patients
Podcast: ASX Briefs – Sam Watson Interview A 149% revenue surge, first‑to‑market GMP MDMA in Australia, and a plan to...
Biocurious: For Bioxyne chief Sam Watson, pot stock success is more than a funky label
Bioxyne is revelling in its status as one of only a few profitable ASX medical cannabis stocks Regulators are tackling...
Bioxyne Boosts FY26 Outlook on Strong Performance and International Growth
Bioxyne lifts FY26 EBITDA guidance to AUD16.5-19m after record H1 FY2026 with AUD31.3m revenue (+149% YoY); expands capacity, enters UK/Germany/LATAM....
Bioxyne receives first psilocybin order
Medicinal cannabis manufacturer Bioxyne has received its first order of GMP-manufactured psilocybin capsules for investigational use in treatment-resistant depression. The...
The fun-guys at Bioxyne chalk up their first psilocybin order
Bioxyne has plenty of ‘shroom to move after first psilocybin sale. A first mover in making psychedelic medications, Bioxyne (ASX:BXN)...